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Abstract 
 
Aim. Pathological diagnosis of adrenocortical carcinoma relies on several microscopic features 
commonly used in combination within different scoring systems that are sometimes subjective 
and/or time consuming. Aim of our study was to investigate the impact of individual pathological 
parameters in the diagnosis and prognosis of adrenocortical carcinoma. Methods and Results. The 
series included 92 malignant cases and a control series of 47 adenomas, all classified according to 
the Weiss score criteria. The presence of the disruption of the reticular network, as highlighted by 
reticulin histochemical staining, was present in all adrenocortical carcinomas and the inclusion of at 
least one of the three following additional parameters - mitotic index >5/50HPF, presence of 
necrosis and presence of vascular invasion - designed an algorithm with a 100% sensitivity and 
specificity to recognize malignant tumors according to the Weiss system, with an easier and more 
practical applicability. Moreover, by multivariate analysis, stage III/IV and mitotic count >9/50HPF 
showed  a strong adverse impact on disease-free and overall survival, leading to the identification of 
three risk groups affected by a significantly different prognosis. Conclusions. The present paper 
defines an easy-to-perform and highly specific and sensitive algorithm for the diagnosis and 
prognostic categorization of malignant adrenocortical tumors.  
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Introduction 
 
Adrenocortical carcinoma is a rare tumor of the adrenal cortex which accounts for no more than 
0.2% of all malignancies, with two peaks of incidence in early childhood and adults over age 60. It 
represents an aggressive disease with up to two thirds of cases having distant metastases at the time 
of diagnosis and a mean survival of less than 30 months,
 1-3 
although combined treatment 
modalities, with special reference to mitotane-based therapy, seems to improve  its outcome. 
4 
The differential diagnosis of carcinomas from adenomas has been based on several microscopic 
features, none of them being alone absolutely indicative of malignancy. 
5, 6
 Despite the majority of 
adrenocortical carcinomas do not represent a diagnostic pitfall in the clinical practice, there are 
several other cases in which the distinction from their benign counterparts is not straightforward. 
These cases are a challenge for the pathologist, since the therapeutic strategy in adrenocortical 
carcinomas is radically different from that of adenomas and an accurate diagnosis is mandatory. 
This issue is also relevant because adrenal tumors are increasingly recognized in clinical practice: 
the widespread use of imaging techniques has resulted in the clinical dilemma of the adrenal 
incidentaloma, 
7
 and although the vast majority of adrenal incidentalomas are benign lesions, in up 
to 12% of cases an incidental adrenocortical carcinoma may be discovered. 
8 
 
Different scoring systems for adrenocortical carcinoma have therefore been developed, using 
mathematical models or numerical scores based on the association of a given threshold for each 
considered parameter to malignancy. 
9-11 
The most widely employed scoring system was proposed 
11
 and revisited in a subsequent report 
12
 by Weiss, and includes nine parameters related to tumor 
structure (loss of clear cytoplasm, presence of diffuse architecture and of necrosis), cytological 
features (atypia, mitotic count, atypical mitotic figures) and invasive properties (sinusoidal, venous 
and capsular invasion).  
Unfortunately, Weiss and other scoring systems are sometimes difficult to apply, subjective 
and/or time consuming, despite several re-visitations and implementations occurred along years to 
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simplify the diagnostic procedure and provide clinically relevant information. 
13-15 
Moreover, in 
paediatric adrenocortical tumors some features included in the Weiss system (namely eosinophilic 
cytoplasm, diffuse architecture or sinusoidal invasion) were found to be less relevant as compared 
to adult tumors, 
16
 thus indicating that the diagnostic work up of children’s tumors should probably 
employ a different panel of pathological factors. 
Recently, a different approach based on the definition of an algorithm centred on mitotic count 
(>5/50HPF), followed by the recognition of other parameters (including nuclear grade, diffuse 
growth pattern and tissue reaction) was proposed, 
17
 and although based on a relatively small series 
of malignant cases – defined by the presence of metastases - it had the advantage of simplifying the 
current diagnostic approach based on numerical scores.  
A second major issue is the distinction between morphologically and clinically malignant 
adrenocortical tumors. Not all adrenal tumors having unequivocal microscopic features of 
malignancy progress to fatal outcome, therefore a better definition of the clinical and pathological 
features that impact on prognosis and a stratification of adrenal cancer patients into prognostic 
categories are needed. Among the most commonly used pathological parameters for the diagnosis 
of adrenocortical carcinoma, mitotic activity and/or proliferative index showed a significant 
association with survival, 
10,12,18
 as age and overall Weiss score did, as well. 
19
 In a very large study 
on metastatic tumors aimed to recognize prognostic rather than diagnostic parameters, multivariate 
analysis identified the presence of a mitotic rate >20x50HPF and the number of organs involved as 
the major factors that influence prognosis in advanced adrenal cancer patients. 
20
  
The aim of the present study was to reconsider the clinical pathological parameters currently 
used in the diagnosis of adrenocortical carcinoma in a large retrospective series of 92 cases 
diagnosed and treated at one Institution, with the aim to revise the classical diagnostic scoring 
systems in an algorithmic approach and to provide a pathologically-based prognostic stratification 
of adrenal cancer patients.  
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Materials and methods 
 
Case selection and pathological classification.  
From a total of 153 cases of primary adrenocortical carcinomas of an adult population included 
in the clinical databases (from 1995 to 2007) of the Divisions of Oncology and Internal Medicine at 
San Luigi Hospital, University of Turin, that serves as national referral centre for this neoplasm, 92 
cases had pathological material retrievable from the files of the Pathology Departments of the 
University of Turin (including 44 consultation cases, operated elsewhere). All cases were 
independently classified by three of us (MV, EB, MP) re-assessing the parameters commonly 
considered in the Weiss system, using 2 to 10 slides for each case. All parameters included in the 
Weiss system 
12
 were recorded independently, together with clinical pathological information such 
as sex, age, location, clinical syndrome, weight and size. For comparison, all cases were also scored 
using the Weiss modified (according to Aubert et al.) 
14
 and Van Slooten 
10
 scoring systems. 
Baseline demographic and clinical data were complete and follow up information were available for 
survival analysis in all but 15 cases, either recent (7 cases) or lost at follow up (8 cases). Tumor 
staging was assessed following recommendations by Sullivan et al. and the Armed Force Institute 
of Pathology. 
21,22
 
Seventy-nine patients bearing stage I to III disease underwent radical surgery followed by 
adjuvant mitotane in 14 of them. The remaining 13 patients, that were not amenable to surgery due 
to locally advanced or metastatic disease, received Mitotane alone (2 patients) or Mitotane plus 
chemotherapy (11 patients) as upfront treatment. One of them was radically operated after 6 cycles 
of chemotherapy plus Mitotane.    
Additional 47 adrenocortical tumors, including all cases observed in the same time period 
having Weiss scores 1 or 2 (16 cases) or adenomas with large size, were collected as a benign tumor 
control group.  
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The main clinical and pathological features of the whole series of 139 adrenocortical tumors are 
summarized in Table 1. 
 
Histochemistry and immunohistochemistry.  
In selected cases, to confirm the adrenocortical nature of the lesion, immunohistochemical 
staining for chromogranin A (Novocastra, Newcastle, UK; clone LK2H10, diluted 1:800), 
synaptophysin (DakoCytomation, Glostrup, DK; clone SY38, diluted 1:100), Melan A 
(DakoCytomation; clone A103, diluted 1:50), alpha-inhibin (Diamedix, Miami, Florida; clone R1, 
diluted 1:75) and CD10 (Santa Cruz Biotech., Santa Cruz, CA; clone 56C6, diluted 1:30) were 
performed. A standard automated (Dako Autostainer, Glostrup, Denmark) immunoperoxidase 
procedure was employed, and immunoreactions were revealed by a biotin-free dextran-chain 
detection system (Envision, Dako), and developed using diaminobenzidine as the chromogen.  
To better evaluate the growth pattern, which is sometimes hard to assess on pure haematoxylin 
and eosin staining, in all cases of adrenal carcinoma with a non-diffuse growth according to the 
original definition of Weiss 
12
 and in all adrenocortical adenomas, a reticulin histochemical staining 
was performed to define the status of the reticulin framework, using a commercially available silver 
impregnation-based kit (Bio Optica, Milan, Italy). Moreover, basal membrane material was 
highlighted by immunohistochemical detection of laminin (Novocastra; clone 4C7, diluted 1:50) 
and collagen type IV (DakoCytomation; clone CIV22, diluted 1:100), as detailed above. The 
presence of a disruption of the reticulin/basal membrane network, similar to that described in the 
setting of other endocrine diseases 
23,24
 was defined by the loss of continuity of reticular fibres or 
basal membrane network evaluated in one high power field (400x), extended to at least one third of 
the lesion. 
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Statistical analysis.  
All data were analyzed with STATISTICA for Windows software version 6.1 (Stat Soft, 
Italy). A level of p<0.05 was considered statistically significant.  
Distribution of single Weiss’s criteria in the overall group of 139 adrenocortical neoplasms was 
evaluated using contingency tables to calculate sensitivity and specificity in relation to the diagnosis 
of adrenocortical carcinoma. To analyze the prognostic impact of all clinical pathological variables 
considered, univariate disease free and overall survival analysis was based on the Kaplan-Meier 
product limit estimate of survival distribution. Clinical pathological parameters considered in 
survival analysis of adrenocortical carcinoma group included: sex, age, location, size, weight, stage, 
Weiss, Weiss modified and van Slooten overall scores, and all single nine histological parameters 
considered in the Weiss scoring system. Unadjusted differences between survival curves were 
tested using the LogRank test. Multivariate analysis of the relative impact on survival of each 
parameter included in the univariate analysis was estimated using the Cox proportional hazards 
regression model.  
 
Results 
 
Distribution of the Weiss’s parameters in adrenocortical tumors. 
The summary of the Weiss’s parameter(s) distribution in the whole series of 139 adrenocortical 
neoplasms is reported in Table 2. None of the parameters reached both 100% sensitivity and 
specificity for the diagnosis of adrenocortical carcinoma. All but three parameters (presence of 
diffuse architecture, nuclear atypia and eosinophilic cytoplasm) were 100% specific for a diagnosis 
of adrenocortical carcinoma. The most sensitive feature was necrosis, that was recognizable in 84% 
of cases, followed by mitotic count exceeding 5 in 50 HPF (71%) and venous invasion (64%). The 
presence of atypical mitoses was highly specific but it was observed in 34% of cases, only.  
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Definition of disrupted reticulin framework. 
A diffuse growth pattern was detected in 79% of adrenocortical carcinomas, and in 9% of 
adrenocortical tumors having a Weiss score <3. Diffuse architecture was considered according to 
Weiss 
12
 as the presence of patternless sheets of cells in more than one-third of the tumor, being 
trabecular, cordonal, columnar, alveolar, or nesting organizations considered as non-diffuse 
patterns. In order to better define the pattern of growth, in all adrenocortical carcinoma cases with a 
non-diffuse architecture at histology, as well as in all 47 adrenocortical adenoma samples, 
histochemical staining for reticulin and immunohistochemical staining with laminin and/or collagen 
IV were performed. A disruption of the reticulin/basal membrane network was detected in all 
adrenocortical carcinoma samples (usually in more than half of the tumor) (Figure 1). In 
adrenocortical tumors with a borderline Weiss value (score 2),  two cases only, having a diffuse and 
trabecular growth rather than the alveolar architecture typical of adrenocortical adenoma, showed 
the loss of a regularly distributed reticulin network. Both such tumors had large size (9 and 6 cm) 
and in addition to a diffuse pattern had either nuclear atypia or eosinophilic cytoplasm, and are alive 
and well at 2 and 3 years follow up in the absence of any adjuvant therapy after surgery. Indeed, the 
morphological (Weiss definition of diffuse growth) and/or histochemical/immunohistochemical 
demonstration of the lack of a well preserved reticulin framework was 100% sensitive and  96% 
specific in the identification of malignant adrenocortical lesions (Weiss score >3).  
   
Design of a simplified diagnostic algorithm. 
The analysis of the frequency of any single Weiss’s parameter in this large series of 
adrenocortical tumors led to design a diagnostic algorithm based on the most sensitive and specific 
features, replacing the classical numerical scoring systems.  
The algorithm takes into consideration the presence of a disrupted reticulin framework, that was 
the single most sensitive feature of malignancy, followed by at least one of the three parameters 
with 100% specificity and highest sensitivity and specificity, namely mitotic count >5x50HPF, 
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presence of necrosis (irrespective of its extent) and/or venous invasion (Figure 2). The retrospective 
evaluation of the whole series of 139 adrenocortical lesion classified according to the Weiss system 
demonstrated that this algorithm was 100%  sensitive and specific for recognizing all cases having a 
Weiss score >3, thus considered malignant.  
 
Prognostic stratification of adrenocortical carcinoma patients.  
A secondary aim of the present study was the prognostic stratification of adrenocortical cancer 
patients. Among the clinical and pathological parameters investigated by means of univariate 
analysis, advanced stage (stage 3 and 4; p=0.007), mitotic count higher than the median value of 9 
(p=0.02), presence of atypical mitoses (p=0.047), Weiss score higher than 6 (p=0.02), and Weiss 
modified score higher than 5 (p=0.02) were significantly associated to a worse overall survival, 
whereas age over the median of 45 years (p=0.04), stage (stage 3 and 4; p=0.008) and mitotic count 
over the median value of 9 (p=0.04) were associated to a shorter disease free survival.  
Multivariate Cox regression model showed an independent prognostic role, at both disease free 
and overall survival analysis, for stage, mitotic count and presence of diffuse growth pattern (Table 
3).  
Based on multivariate analysis, adrenocortical carcinomas were re-classified into three risk 
groups according to the status of the independent prognostic factors (diffuse growth pattern was 
excluded, being part of the diagnostic algorithm as the first step criterion for adrenal carcinoma). 
Survival analysis demonstrated that the stratification of adrenocortical cancer patients according to 
the scheme proposed was strongly correlated to disease free (p<0.007) and overall (p<0.005) 
outcome status (Figure 3). Mean disease-free survival were 61.9, 17.3, 12.2 months, and overall 
survival were not attained, 66.2, 26.4 months in low, intermediate and high risk groups, 
respectively. 
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Discussion 
In the present paper, a novel diagnostic approach and a prognostic stratification of adrenal 
cancer was defined by extensive analysis of clinical pathological features in a large series of tumors. 
The major relevant findings of our study were i) the definition of the presence of disrupted reticulin 
framework as an hallmark for the diagnosis of adrenocortical carcinoma; ii) the proposal of a 
simplified diagnostic algorithm based on the recognition of unequivocal malignancy-related 
features rather than on numerical scores; iii) the prognostic categorization of adrenal cancer patients 
into three groups characterized by significantly different outcome. 
Our first observation stemmed by the re-evaluation of the concept of diffuse growth pattern, that 
in both Weiss’ original papers 
11,12 
and also in a recent study 
17
 was highlighted as a major 
diagnostic feature for adrenal cancer, although less relevant for others. 
14
 By morphological analysis 
and appropriate histochemical and immunohistochemical reactions, all adrenocortical carcinomas 
were found to have a disruption of the reticulin framework, irrespective of the growth pattern. In 
other terms, not only diffuse growth but also trabecular, cordonal, nesting or other patterns were 
affected by the loss of the reticulin/basal membrane network typical of normal or adenomatous 
adrenal cortex, thus reassessing the concept of growth pattern as a primary feature in adrenocortical 
carcinoma diagnosis. Interestingly, such observation fits with some recent findings from our group 
on the expression by adrenal cancer cells of proteins involved in matrix digestion, such as matrix-
metalloproteinase type 2, 
25
 and on the de-regulation of gene transcription of laminin isoforms in 
malignant as compared to non neoplastic adrenal tissue (Volante M et al, submitted).  
From a diagnostic point of view, the presence of a disrupted reticulin network was a highly 
sensitive and specific feature in adrenocortical carcinoma diagnosis. Since its recognition is easy 
and equivocal cases might be solved by reticulin staining and/or laminin and type IV collagen 
immunohistochemistry, we entered this criterion as the primary step of the diagnostic algorithm 
herein proposed. The additional presence of at least one of the malignancy-related features 
conventionally considered in several endocrine tumors (necrosis, high mitotic rate and venous 
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vessel invasion) raised up to 100% the sensitivity and specificity of the algorithm for a diagnosis of 
malignancy. The decision of proposing a two-step algorithm, including at a second level additional 
microscopic features of malignancy, was related to the finding of disruption of the reticulin 
framework in two cases of large size adenomas, which reached a Weiss score 2: although clinical 
data were consistent in both cases with a benign disease at the last follow up, the biological 
meaning of the observed reticulin alteration remains to be defined.  
This simplified scheme has the major advantage of reducing the analysis of other parameters 
such as nuclear atypia, eosinophilic cytoplasm, sinusoidal and capsular invasion, that although 
commonly found in malignant lesions may be of equivocal definition and are sometimes subjective, 
especially in pathology laboratories lacking a specific experience in endocrine diseases. It is 
important to underline that in the great majority of cases (84%) at least two of the malignancy-
related parameters were easily recognizable together with reticulin framework abnormalities, 
whereas in only a minority of cases did the definition of malignancy rely on one single parameter 
(either necrosis, mitotic activity or venous invasion).  
A step forward in our algorithmic approach was the identification of risk groups of adrenal 
cancer patients. In general terms, literature data on prognosis of adrenal cancer indicate a plethora 
of morphological, clinical or molecular features impacting on the clinical behaviour of this 
neoplasm, 
19,20,25-29
 although some studies are biased by the sample size, unclear diagnostic criteria, 
and/or patients’ selection. In agreement with literature data, in the present study multivariate 
survival analysis confirmed that diffuse architecture, stage and mitotic index represent the most 
relevant prognostic factors in adrenal cancer. Concerning mitotic index, the most significant 
prognostic cut off in our series was 9x50HPF (representing the median value), at variance with 
other Authors that used a level of 20x50HPF. 
12,20
 However, irrespective of the cut off values 
employed, it is noteworthy that the vast majority of published series agrees that mitotic activity 
represents the tumor characteristic with the strongest impact on survival.  
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The clinical impact of the prognostic factors pointed out in the present multivariate statistical 
model was further confirmed by survival analysis of the three risk groups identified according to the 
presence or absence of relevant adverse factors. The relevance of those findings, as compared to 
other studies in the literature 
30
 is related to the large number of cases here analyzed, diagnosed and 
treated in one Institution. A validation set based on an external cohort of cases would be useful to 
strengthen the applicability of this algorithm. 
In summary, in the present paper an easy-to-perform and highly specific and sensitive algorithm 
for the diagnosis of malignant adrenocortical tumors was designed, and a clinically relevant 
prognostic categorization of adrenal cancer patients was additionally provided.  
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Figure legends 
 
Figure 1. Histochemical and immunohistochemical analysis of the reticulin framework in 
adrenocortical tumors. The presence of a disruption of the reticulin network was defined by the loss 
of continuity of reticular fibres in one high power field (400x) (a). The dotted line draws a virtual 
pathway connecting two opposite sides of a tumor field in malignant tumors. This connection was 
not possible in most adrenocortical adenomas, even in the case of large tumor size (b, 
adrenocortical adenoma, 9 cm in diameter), due to the integrity of the reticulin network. 
Conversely, it was a consistent finding in adrenocortical carcinomas (c) and was paralleled by the 
loss of basal membrane network (d, laminin immunohistochemistry), as compared to non-tumoral 
adrenal cortex (c and d, insets) 
(Original magnifications: a: 400x; b: 100x, c and d, including insets: 200x) 
 
Figure 2. Simplified algorithm for the diagnosis and prognostic categorization of adrenocortical 
carcinomas (see text for details). ACA: adrenocortical adenoma. ACC: adrenocortical carcinoma. 
 
Figure 3. Disease-free survival and overall survival curves of adrenocortical carcinomas segregated 
into three risk groups according to the proposed algorithm. 
 
 
. 
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Table 1. Clinico-pathological features of a series of 92 adrenocortical carcinomas and 47 adrenocortical adenomas with large size and/or Weiss 
score 1 or 2.  
Diagnosis (#) F/M 
ratio 
Age, mean 
[range] 
Location Size (cm), mean 
[range] 
Weight (grams) 
mean, [range] 
Functional status Outcome 
        
Adrenocortical  
carcinoma (92) 
1.5 46 
[20-85] 
LA 48* 
RA 45* 
11.4 
[1.6-25] 
428 
[8-3100] 
NF: 50 
Cortisol: 13 
Aldosterone: 6 
Androgens: 8 
not known: 15 
NED: 32 
AWD: 15 
DOD: 28 
recent cases: 7 
lost: 8 
 
        
Adrenocortical  
adenoma (47) 
3.2 53 
[15-77] 
LA 23 
RA 24 
4 
[1-10] 
39 
[4-150] 
NF: 13 
Cortisol: 18 
Aldosteron: 15 
not known: 1 
NED: 47 
Legend. LA: left adrenal; RA: right adrenal; * one case had bilateral tumors, NF: not functioning; NED: no evidence of disease; AWD: alive 
with disease; DOD: died of disease.  
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Table 2. Distribution of Weiss scoring system pathological parameters in 139 adrenocortical 
tumors, including 92 carcinomas and 47 adenomas.  
 
Parameter 
Frequency 
Weiss <3           Weiss >3 
 
SN 
 
SP 
 
PPV 
 
NPV 
 
      
Mitoses >5x50HPF 0/47 65/92 71% 100% 100% 64% 
Atypical mitoses 0/47 31/92 34% 100% 100% 43% 
Necrosis 0/47 77/92 84% 100% 100% 76% 
Venous invasion 0/47 59/92 64% 100% 100% 59% 
Sinusal invasion 0/47 52/92 57% 100% 100% 54% 
Capsular invasion 0/47 50/92 54% 100% 100% 53% 
Diffuse growth 4/47 73/92 79% 91% 95% 69% 
Nuclear atypia 9/47 78/92 85% 81% 90% 73% 
Clear cells <25% 6/47 60/92 65% 87% 91% 56% 
 
      
SN: sensitivity; SP: specificity; PPV: positive predictive value; NPV: negative predictive value. 
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Table 3. Multivariate analysis of disease-free and overall survival in adrenocortical carcinomas 
according to clinico-pathological parameters. 
________________________________________________________________________________ 
Disease free survival  Hazard Ratio  95% Confidence Interval  p 
Stage  
1-2    
3-4    2.064    1.283-3.319    0.003 
Mitoses 
< 9    
>9    1.021   1.004-1.038    0.016 
Diffuse architecture 
Absent    
Present   0.402   0.196-0.822    0.013 
 
Overall survival  Hazard Ratio  95% Confidence Interval  p 
Stage  
1-2    
3-4    2.349   1.285-4.293    0.006 
Mitoses 
< 9    
>9    1.033   1.012-1.053    0.001 
Diffuse architecture  
Absent    
Present   0.363   0.145-0.905    0.03 
________________________________________________________________________________ 
 Age, sex and atypical mitoses failed to enter both Cox models 
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